New drug targets Hard-to-Treat cancers in major trial
NCT ID NCT06695845
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This phase 2 trial is testing a drug called zanidatamab in 200 adults with advanced HER2-positive solid tumors, including breast, stomach, lung, and other cancers that have worsened after at least one prior treatment. The drug is given by IV and aims to shrink or control tumor growth. Researchers will measure how many participants respond and how long the response lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Oncologists
WITHDRAWNChicago Ridge, Illinois, 60415, United States
-
Alliance Cancer Specialists
WITHDRAWNHorsham, Pennsylvania, 19044, United States
-
Arizona Oncology Associates, PC - NAHOA
WITHDRAWNPrescott, Arizona, 86301, United States
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
Barbara Ann Karmanos Cancer Institute
WITHDRAWNDetroit, Michigan, 48201, United States
-
Blue Ridge Cancer Care
WITHDRAWNRoanoke, Virginia, 24014, United States
-
Chonnam National University Hwasun Hospital
RECRUITINGHwasun-Eup, Hwasun-Gun, 58115, South Korea
-
Florida Cancer Specialists - East
WITHDRAWNWest Palm Beach, Florida, 33401, United States
-
Florida Cancer Specialists - Lake Nona
ACTIVE_NOT_RECRUITINGOrlando, Florida, 32827, United States
-
Florida Cancer Specialists - North
WITHDRAWNSt. Petersburg, Florida, 33705, United States
-
Florida Cancer Specialists - South
WITHDRAWNFort Myers, Florida, 33901, United States
-
Hospital Regional Universitario de Malaga - Hospital General
RECRUITINGMálaga, 29010, Spain
-
Korea University Guro Hospital
RECRUITINGGuro-gu, Seoul, 04524, South Korea
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
National Cancer Center Suwon
RECRUITINGSuwon, Gyeonggi-do, 10408, South Korea
-
Rocky Mountain Cancer Center
RECRUITINGLittleton, Colorado, 80120, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Samsung Medical Center
RECRUITINGGangnam-gu, Seoul, 06351, South Korea
-
Seoul National University Bundang Hospital
RECRUITINGSeoul, 13620, South Korea
-
Seoul National University Hospital
RECRUITINGJongno-gu, Seoul, 03080, South Korea
-
Severance Hospital
RECRUITINGSeodaemun-gu, Seoul, 03722, South Korea
-
Tennessee Cancer Specialists
WITHDRAWNKnoxville, Tennessee, 37909, United States
-
Texas Oncology - DFW
RECRUITINGDallas, Texas, 75246, United States
-
Texas Oncology - San Antonio
WITHDRAWNSan Antonio, Texas, 78217, United States
-
Texas Oncology - West Texas
WITHDRAWNAmarillo, Texas, 79124, United States
-
The Catholic University of Korea Seoul St. Mary's Hospital
RECRUITINGSeoul, 04524, South Korea
-
The Catholic University of Korea St Vincent's Hospital
RECRUITINGSuwon, Gyeonggi-do, 10408, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanidatamab (a drug given by IV infusion that targets HER2-positive cancer cells)
What this could lead to
If successful, this could provide a new treatment option for people with several types of HER2-positive cancers that have stopped responding to other therapies.
What could go wrong
This is an early-phase trial with no placebo group, so results are preliminary. The drug may not shrink tumors in all participants, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.